Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
DAVENPORT & Co LLC lessened its position in shares of GSK plc (NYSE:GSK – Free Report) by 4.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission.
“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.
chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...
In a statement, GSK chief commercial officer Luke Miels said that the drug "complements [the company's] growing portfolio in gastrointestinal cancers," which also includes anti-PD-1 antibody ...
Luke Miels, GSK’s chief commercial officer, said: “This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical ...
GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06.
The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of ...
Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback